Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06331624
Other study ID # GRI-0621-IPF-02
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 2024
Est. completion date January 2025

Study information

Verified date March 2024
Source GRI Bio Operations, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks. Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers). An interim analysis will be performed when 24 subjects complete 6 weeks of treatment (approximately 8 placebo subjects).


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 40 Years to 85 Years
Eligibility Inclusion Criteria: 1. Male or female subjects 40 through 85 years of age, inclusive. 2. Confirmed diagnosis of IPF with clinical features consistent with the current clinical practice guidelines for IPF. 3. FVC > 50% predicted value within 4 weeks of Screening. 4. FEV1/FVC ratio > 0.65 within 4 weeks of Screening. 5. Diffusion capacity for carbon monoxide corrected for hemoglobin (DLCOc) > 30%predicted value within 4 weeks of Screening. 6. Life expectancy of at least 12 months. 7. Willing and able to follow the study required visits and assessments. For Sub-Study subjects, willing and able to undergo BAL procedures at Screening and at Week 12. 8. Willing and able to provide written informed consent prior to study-related procedures. Exclusion Criteria: 1. Initiation of any approved or investigational IPF therapy or oral corticosteroids (> 10 mg/day) within 4 weeks of Screening. Subjects already on approved IPF therapies must remain on their current medication from Screening until the last study visit. 2. High resolution computerized tomography (HRCT) pattern showing emphysema more than the extent of fibrosis of the lung area within 12 months of Screening. 3. Acute exacerbation of IPF within 6 months of Screening (Collard et al., 2016). 4. Requiring supplemental O2 > 4 liters/min to maintain peripheral arterial O2 saturation (SpO2) > 88% at rest. O2 saturation at screening or baseline that is < 88% at rest. 5. Any condition with unacceptable risk for bronchoscopy (for Sub-Study subjects only). 6. Current or recent history of clinically significant medical condition, laboratory abnormality, or illness that could place the subject at risk or compromise the quality of the study data as determined by the Investigator. 7. Significant coronary artery disease (i.e., myocardial infarction within 6 months or unstable angina within 1 month of Screening). 8. An upper or lower respiratory tract infection, presence of or suspected emphysema, within 4 weeks of Screening. 9. Eye exam indicating night blindness within 6 months of Screening, or at Screening. 10. Bone Mineral Density t-score of -4.0 (severe osteoporosis) within 6 months of Screening, or at Screening. 11. Screening QT of >450 for men and >470 for women. 12. History of renal impairment as deemed clinically relevant by the investigator OR eGFR <60ml/min/1.73m2 within 60 days of Screening and a Screening eGFR of <60ml/min/1.73m2. 13. History of hepatic impairment as deemed clinically relevant by the investigator OR ALT or AST >2 x ULN OR moderate and severe hepatic impairment as defined using the Child-Pugh scoring system (i.e., Child-Pugh B and C). 14. A history of hypertriglyceridemia (documented TG of >2.0mmol/L at Screening); a history of pancreatitis from any cause; uncontrolled dyslipidemia with LDL-c >4.9mmol/L and an HDL-c <1.3 mmol/L for women and <1.0 for men, despite optimized treatment. 15. Use of moderate or strong inhibitors of CYP2C8 (e.g. gemfibrazol, trimethoprim, clopidogrel) or inducers of CYP2C8 (e.g. rifampin) from 7 days or 5 half-lives, whichever is longer, before the first administration of GRI-0621 until cessation of GRI-0621 administration. 16. Subjects who report any active suicidal ideation (SI) or behavior (SB) (i.e. Columbia Suicide Severity Rating Scale (C-SSRS) scores 4 or greater for SI and any positive scores for SB) during Screening or any past history thereof. 17. Current smoker (i.e., use of tobacco products within the last 3 months) of Screening. 18. Current or recent history of drug or alcohol abuse within 12 months of Screening. 19. Participation in any other investigational drug study within 4 weeks of Screening or within 5 times the elimination half-life of an investigational drug. 20. Females who are pregnant or breastfeeding, or if of child-bearing potential unwilling to practice two highly effective forms of contraception for at least 1 month prior to initiation of the study drug, during the study, and for 1 month after discontinuing the study drug (e.g., abstinence, intrauterine device or system, combination of barrier and spermicide, hormonal contraceptive, surgical sterilization, or male partner sterilization). 21. Males, if sexually active, unwilling to practice two highly effective forms of contraception during the study (e.g., condom, or surgical sterilization). 22. History of hypersensitivity or intolerance to oral tazarotene.

Study Design


Intervention

Drug:
Tazarotene (GRI-0621)
Oral 4.5mg soft gel capsule
Placebo
Oral 4.5mg soft gel capsule

Locations

Country Name City State
United States Newport Native MD, Inc. Newport Beach California
United States Southeastern Research Center Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
GRI Bio Operations, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory - Pulmonary Function Effect of GRI-0621 on pulmonary function (FEV1, FVC, and FEV1/FVC ratio) at baseline and after 6 weeks and 12 weeks of treatment. 6 Weeks and 12 Weeks
Primary Safety and Tolerability of oral GRI-0621 General overall safety and tolerability of oral GRI-0621 as compared to placebo will be assessed by evaluating the following safety parameters:
Adverse events (occurrence and type)
Clinical Laboratory Measurements (normal/abnormal)
Vital signs (normal/abnormal)
12 Weeks
Secondary Change from baseline biomarkers Change from baseline in biomarkers (PRO-C3, PRO-C6, C1M, C3M, C6M, VICM, CPa9-HNE, PRO-C4, PRO-C5, CTX-III, ELP-3, C4Ma3) 12 Weeks
Secondary Plasma concentrations of GRI-0621 Pharmacokinetic analysis 12 Weeks
Secondary Pharmacodynamics of GRI-0621 in blood (Study Population) Measure of NKT1 cell activation inhibition in blood 6 Weeks and 12 Weeks
Secondary Pharmacodynamics of GRI-0621 in BAL fluid (Optional Sub-Study) Measure of NKT1 cell activation inhibition from bronchoalveolar lavage (BAL) fluid 12 Weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05984992 - The First-in-human Study of SRN-001 in Healthy Participants Phase 1
Active, not recruiting NCT04312594 - Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT03865927 - GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03979430 - Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study N/A
Enrolling by invitation NCT04905693 - Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Phase 3
Not yet recruiting NCT06241560 - A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood Phase 2
Terminated NCT04419558 - Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 3
Completed NCT03725852 - A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Terminated NCT03573505 - An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT04148157 - Quality of Life in IPF - Patient and Physician Perceptions
Completed NCT03222648 - Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis N/A
Not yet recruiting NCT06422884 - A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) Phase 2
Completed NCT02268981 - Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) N/A
Completed NCT02257177 - RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients Phase 1/Phase 2
Withdrawn NCT01524068 - A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Phase 2
Enrolling by invitation NCT01382368 - Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Phase 4
Completed NCT01199887 - Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis Phase 1
Completed NCT01110694 - Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
Active, not recruiting NCT02951416 - Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
Terminated NCT00981747 - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Phase 2/Phase 3